JD Health International Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Enlin Jin

Algemeen directeur

CN¥8.4m

Totale compensatie

Percentage CEO-salaris	15.0%
Dienstverband CEO	3.2yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Enlin Jin's beloning veranderd ten opzichte van JD Health International's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥8m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥1b
Dec 31 2022	CN¥8m	CN¥1m	CN¥380m
Sep 30 2022	n/a	n/a	-CN¥7m
Jun 30 2022	n/a	n/a	-CN¥395m
Mar 31 2022	n/a	n/a	-CN¥734m
Dec 31 2021	CN¥3m	CN¥301k	-CN¥1b

Compensatie versus markt: De totale vergoeding ($USD 1.16M ) Enlin } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 905.89K ).

Compensatie versus inkomsten: De vergoeding van Enlin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Enlin Jin (43 yo)

3.2yrs

Tenure

CN¥8,385,000

Compensatie

Mr. Enlin Jin is Chief Executive Officer & Executive Director of JD Health International Inc. from September 06, 2021. Mr. Jin has extensive experience in pharmaceuticals and TMT industry. He serves as the...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Enlin Jin	CEO & Executive Director	3.2yrs	CN¥8.39m	0.011% HK$ 9.6m
Ying Wu	Independent Non-Executive Director	2.6yrs	CN¥818.00k	0.00030% HK$ 267.5k
Qiangdong Liu	Chairman	4.2yrs	CN¥407.82m	0.56% HK$ 495.3m
Qingqing Yi	Non-Executive Director	4.3yrs	geen gegevens	geen gegevens
Xingyao Chen	Independent Non-Executive Director	4yrs	CN¥476.00k	0.00018% HK$ 160.5k
Ling Li	Independent Non-Executive Director	4yrs	CN¥476.00k	0.00018% HK$ 160.5k
Jiyu Zhang	Independent Non-Executive Director	3.7yrs	CN¥463.00k	0.00019% HK$ 169.4k

4.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6618 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

JD Health International Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021